Zynex Inc. (ZYXI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to earnings of $0.04 per share a year ago. These figures are ...

Fintel reports that on August 1, 2025, HC Wainwright & Co. downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.05 per share a year ago.

Zynex (ZYXI) delivered earnings and revenue surprises of 40% and 0.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zynex Inc. ZYXI recently announced the completion of the clinical verification trial of its NiCO pulse oximeter, which was overseen by anesthesiologist Dr. David MacLeod at Duke University. NiCO ...

Zynex, Inc. (NASDAQ:ZYXI) shareholders are no doubt pleased to see that the share price has bounced 29% in the last month, although it is still struggling to make up recently lost ground ...

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.05 per share a year ago.

In September, ZYXI announced the FDA clearance of its new TensWave device. The TensWave device, by prescription only, builds on Zynex's strong legacy of innovation in pain management.